Overview

Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD) patients. Dyskinesias are abnormal movements, often caused by the standard treatment for PD symptoms, levodopa. In this study, we will test if biochemical devices are equal to the clinical rating system in measuring dyskinesias.
Details
Lead Sponsor:
US Department of Veterans Affairs
VA Office of Research and Development
Collaborator:
Oregon Health and Science University
Treatments:
Levodopa